<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39424883</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Autoantibodies to protein S may explain rare cases of coagulopathy following COVID-19 vaccination.</ArticleTitle><Pagination><StartPage>24512</StartPage><MedlinePgn>24512</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24512</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75514-x</ELocationID><Abstract><AbstractText>While Coronavirus disease 2019 (COVID-19) vaccines have proven to be both effective and generally safe, rare but severe adverse events following immunization (AEFIs) are described. Autoantibodies to platelet factor-4 are associated with catastrophic thrombotic AEFIs, but comprehensive investigations of other autoantibodies are lacking. We aimed to detect and describe autoantibodies targeting coagulation-related proteins in a population-wide cohort (SWEDEGENE) including AEFIs attributed to COVID-19 vaccines in Sweden. Subjects were recruited from December 2020 to October 2022 and were stratified based on diagnosis and COVID-19 exposure. Screening was carried out in two phases, with a multiplex bead-based assay in the first subset (until September 2021) and with targeted assays for the second (until October 2022). Positivity was defined based on absolute, relative, and biological/technical thresholds. Patients with coagulation-related AEFIs were older and the Vaxzevria vaccine was overrepresented in this group. Two cases had antiphospholipid antibodies but none had PF4 antibodies. We identified six positives for protein S autoantibodies. Protein S concentrations were negatively correlated with autoantibody response in patients with immunoreactivity and functional analysis revealed low protein S activity in three subjects. Our population-wide analysis reveals cases with autoantibodies against protein S which possibly underlie coagulopathic AEFIs.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yalcinkaya</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden. ahmet.yalcinkaya@imbim.uu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, Turkey. ahmet.yalcinkaya@imbim.uu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavalli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Sciences, Clinical Pharmacogenomics, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aranda-Guillén</LastName><ForeName>Maribel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine (Solna), Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cederholm</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Güner</LastName><ForeName>Almira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rietrae</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mildner</LastName><ForeName>Hedvig</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behere</LastName><ForeName>Anish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit for Clinical Pediatrics, Department of Women's and Children's Health (Solna), Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mugabo</LastName><ForeName>Constantin Habimana</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Unit for Clinical Pediatrics, Department of Women's and Children's Health (Solna), Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnsson</LastName><ForeName>Anette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unit for Clinical Pediatrics, Department of Women's and Children's Health (Solna), Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakshmikanth</LastName><ForeName>Tadepally</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Unit for Clinical Pediatrics, Department of Women's and Children's Health (Solna), Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodin</LastName><ForeName>Petter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit for Clinical Pediatrics, Department of Women's and Children's Health (Solna), Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Inflammation, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadelius</LastName><ForeName>Mia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Clinical Pharmacogenomics, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallberg</LastName><ForeName>Pär</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Clinical Pharmacogenomics, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landegren</LastName><ForeName>Nils</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Solna), Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017293">Protein S</NameOfSubstance></Chemical><Chemical><RegistryNumber>37270-94-3</RegistryNumber><NameOfSubstance UI="D010978">Platelet Factor 4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017293" MajorTopicYN="Y">Protein S</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001778" MajorTopicYN="N">Blood Coagulation Disorders</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010978" MajorTopicYN="N">Platelet Factor 4</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoantibodies</Keyword><Keyword MajorTopicYN="N">Blood coagulation disorders</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Protein S</Keyword><Keyword MajorTopicYN="N">Vaccines/adverse effects</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>23</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39424883</ArticleId><ArticleId IdType="pmc">PMC11489816</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75514-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75514-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Flanagan, K. L., MacIntyre, C. R., McIntyre, P. B. &amp; Nelson, M. R. SARS-CoV-2 vaccines: Where are we now?. J. Allergy Clin. Immunol. Pract.9, 3535–3543. 10.1016/j.jaip.2021.07.016 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363243</ArticleId><ArticleId IdType="pubmed">34400116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Q. et al. Evaluation of the safety profile of COVID-19 vaccines: A rapid review. BMC Med.19, 173. 10.1186/s12916-021-02059-5 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8315897</ArticleId><ArticleId IdType="pubmed">34315454</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, C. et al. Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety. Sci. Rep.12, 10946. 10.1038/s41598-022-13809-7 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9243073</ArticleId><ArticleId IdType="pubmed">35768434</ArticleId></ArticleIdList></Reference><Reference><Citation>Vera-Lastra, O. et al. New onset autoimmune diseases after the sputnik vaccine. Biomedicines11, 1898. 10.3390/biomedicines11071898 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10377489</ArticleId><ArticleId IdType="pubmed">37509537</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsoi, J. Y. H. et al. Autoantibodies against angiotensin-converting enzyme 2 (ACE2) after COVID-19 infection or vaccination. J. Med. Virol.95, e29313. 10.1002/jmv.29313 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38100626</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuben, R. C. &amp; Adogo, L. Y. SARS-CoV-2 vaccines-induced thrombotic thrombocytopenia: Should we consider immuno-hypersensitivity?. Rev. Saude Publica55, 70. 10.11606/s1518-8787.2021055003855 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522756</ArticleId><ArticleId IdType="pubmed">34730750</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner, A. J. et al. Antithrombin III deficiency-induced coagulopathy in the context of COVID-19: A case series. British Journal of Haematology194, 1007–1009. 10.1111/bjh.17575 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8239505</ArticleId><ArticleId IdType="pubmed">34053064</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Morena-Barrio, M. E. et al. A pilot study on the impact of congenital thrombophilia in COVID-19. Eur. J. Clin. Invest.51, e13546. 10.1111/eci.13546 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250296</ArticleId><ArticleId IdType="pubmed">33738814</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva, B. R. S. et al. Downregulation of the protein C signaling system is associated with COVID-19 hypercoagulability-a single-cell transcriptomics analysis. Viruses14, 2753. 10.3390/v14122753 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9785999</ArticleId><ArticleId IdType="pubmed">36560757</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirumamilla, Y., Almerstani, Y., Marcus, H. &amp; Bachuwa, G. Protein S deficiency and COVID-19: A brutal combination leading to acute submassive bilateral pulmonary embolism. Cureus15, e41560. 10.7759/cureus.41560 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10405865</ArticleId><ArticleId IdType="pubmed">37554606</ArticleId></ArticleIdList></Reference><Reference><Citation>Joan, L., Daniella, A. S. &amp; Michael, N. COVID-19, immunothrombosis and venous thromboembolism: Biological mechanisms. Thorax76, 412. 10.1136/thoraxjnl-2020-216243 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33408195</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim, M. M. S. &amp; Wood, J. P. Dysregulation of Protein S in COVID-19. Best Pract. Res. Clin. Haematol.35, 101376. 10.1016/j.beha.2022.101376 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9395234</ArticleId><ArticleId IdType="pubmed">36494145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, P. et al. Varicella and thrombotic complications associated with transient protein C and protein S deficiencies in children. Eur. J. Pediatr.153, 646–649 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7957422</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamprinou, M., Sachinidis, A., Stamoula, E., Vavilis, T. &amp; Papazisis, G. COVID-19 vaccines adverse events: Potential molecular mechanisms. Immunol. Res.71, 356–372. 10.1007/s12026-023-09357-5 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9821369</ArticleId><ArticleId IdType="pubmed">36607502</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustamante, J. G., Goyal, A. &amp; Singhal, M. in StatPearl (StatPearls Publishing, St. Petersburg, 2024).</Citation></Reference><Reference><Citation>Abdel-Wahab, N., Talathi, S., Lopez-Olivo, M. A. &amp; Suarez-Almazor, M. E. Risk of developing antiphospholipid antibodies following viral infection: A systematic review and meta-analysis. Lupus27, 572–583. 10.1177/0961203317731532 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28945149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo, Y. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med.12, 3876. 10.1126/scitranslmed.abd3876 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Martínez, D., Torres, Z., Amezcua-Guerra, L. M. &amp; Pineda, C. Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19?. Clin. Rheumatol.40, 3015–3019. 10.1007/s10067-021-05724-5 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8024929</ArticleId><ArticleId IdType="pubmed">33826045</ArticleId></ArticleIdList></Reference><Reference><Citation>Devreese, K. M. J., Linskens, E. A., Benoit, D. &amp; Peperstraete, H. Antiphospholipid antibodies in patients with COVID-19: A relevant observation?. J. Thromb. Haemost.18, 2191–2201. 10.1111/jth.14994 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361253</ArticleId><ArticleId IdType="pubmed">32619328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gkrouzman, E., Barbhaiya, M., Erkan, D. &amp; Lockshin, M. D. Reality check on antiphospholipid antibodies in COVID-19–associated coagulopathy. Arthritis Rheumatol.73, 173–174. 10.1002/art.41472 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32901454</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully, M. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med.384, 2202–2211. 10.1056/NEJMoa2105385 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112532</ArticleId><ArticleId IdType="pubmed">33861525</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz, N. H. et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med.384, 2124–2130. 10.1056/NEJMoa2104882 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112568</ArticleId><ArticleId IdType="pubmed">33835768</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh, K. J., Baumblatt, J., Chege, W., Goud, R. &amp; Nair, N. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the vaccine adverse event reporting system (VAERS). Vaccine39, 3329–3332. 10.1016/j.vaccine.2021.04.054 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086806</ArticleId><ArticleId IdType="pubmed">34006408</ArticleId></ArticleIdList></Reference><Reference><Citation>Cines, D. B. &amp; Bussel, J. B. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N. Engl. J. Med.384, 2254–2256. 10.1056/NEJMe2106315 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8063912</ArticleId><ArticleId IdType="pubmed">33861524</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher, A. et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med.384, 2092–2101. 10.1056/NEJMoa2104840 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Favas, T. T. et al. Thrombotic and thromboembolic complications after vaccination against COVID-19: A systematic review. Cureus15, e37275. 10.7759/cureus.37275 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10167937</ArticleId><ArticleId IdType="pubmed">37182082</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallberg, P. et al. SWEDEGENE—a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions. Pharmacogenomics J.20, 579–585. 10.1038/s41397-020-0148-3 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7375949</ArticleId><ArticleId IdType="pubmed">31949290</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordström, P., Ballin, M. &amp; Nordström, A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: A retrospective, total population cohort study in Sweden. Lancet399, 814–823. 10.1016/S0140-6736(22)00089-7 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8816388</ArticleId><ArticleId IdType="pubmed">35131043</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg-Morris, L. et al. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: Population based cohort study. BMJ383, e076990. 10.1136/bmj-2023-076990 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10666099</ArticleId><ArticleId IdType="pubmed">37993131</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlstad, Ø. et al. SARS-CoV-2 vaccination and myocarditis in a nordic cohort study of 23 million residents. JAMA Cardiol.7, 600–612. 10.1001/jamacardio.2022.0583 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9021987</ArticleId><ArticleId IdType="pubmed">35442390</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomara, C. et al. COVID-19 vaccine and death: Causality algorithm according to the WHO eligibility diagnosis. Diagnostics (Basel)11, 955. 10.3390/diagnostics11060955 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8229116</ArticleId><ArticleId IdType="pubmed">34073536</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Voyer, T. et al. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency. Nature623, 803–813. 10.1038/s41586-023-06717-x (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10665196</ArticleId><ArticleId IdType="pubmed">37938781</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcinkaya, A. et al. No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines. npj Vaccines9, 42. 10.1038/s41541-024-00829-9 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10883980</ArticleId><ArticleId IdType="pubmed">38388530</ArticleId></ArticleIdList></Reference><Reference><Citation>Abolhassani, H. et al. X-linked TLR7 deficiency underlies critical COVID-19 pneumonia in a male patient with ataxia-telangiectasia. J. Clin. Immunol.42, 1–9. 10.1007/s10875-021-01151-y (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8536475</ArticleId><ArticleId IdType="pubmed">34686943</ArticleId></ArticleIdList></Reference><Reference><Citation>Platton, S. et al. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J. Thromb. Haemost.19, 2007–2013. 10.1111/jth.15362 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8236994</ArticleId><ArticleId IdType="pubmed">33973336</ArticleId></ArticleIdList></Reference><Reference><Citation>R Foundation for Statistical Computing. R: A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria, 2023).</Citation></Reference><Reference><Citation>Knight, R. et al. Association of COVID-19 with major arterial and venous thrombotic diseases: A population-wide cohort study of 48 million adults in England and wales. Circulation146, 892–906. 10.1161/CIRCULATIONAHA.122.060785 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484653</ArticleId><ArticleId IdType="pubmed">36121907</ArticleId></ArticleIdList></Reference><Reference><Citation>Núria, M.-B. et al. The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications. Heart10.1136/heartjnl-2023-323483 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11041555</ArticleId><ArticleId IdType="pubmed">38471729</ArticleId></ArticleIdList></Reference><Reference><Citation>Cari, L. et al. Thrombotic events with or without thrombocytopenia in recipients of adenovirus-based COVID-19 vaccines. Front. Cardiovasc. Med.9, 967926. 10.3389/fcvm.2022.967926 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556888</ArticleId><ArticleId IdType="pubmed">36247442</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujinami, R. S., von Herrath, M. G., Christen, U. &amp; Whitton, J. L. Molecular mimicry, bystander activation, or viral persistence: Infections and autoimmune disease. Clin. Microbiol. Rev.19, 80–94. 10.1128/cmr.19.1.80-94.2006 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360274</ArticleId><ArticleId IdType="pubmed">16418524</ArticleId></ArticleIdList></Reference><Reference><Citation>Sher, E. K. et al. Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases. Life Sci319, 121531. 10.1016/j.lfs.2023.121531 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9969758</ArticleId><ArticleId IdType="pubmed">36858313</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng, K. et al. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: A population-based cohort study. eClinicalMedicine63, 102154. 10.1016/j.eclinm.2023.102154 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10458663</ArticleId><ArticleId IdType="pubmed">37637754</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher, A. et al. Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood138, 1269–1277. 10.1182/blood.2021012938 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8294553</ArticleId><ArticleId IdType="pubmed">34280256</ArticleId></ArticleIdList></Reference><Reference><Citation>Schönborn, L. et al. Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure. Blood142, 2305–2314. 10.1182/blood.2023022136 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10862238</ArticleId><ArticleId IdType="pubmed">37883798</ArticleId></ArticleIdList></Reference><Reference><Citation>Warkentin, T. E. et al. Adenovirus-associated thrombocytopenia, thrombosis, and VITT-like antibodies. N. Engl. J. Med.389, 574–577. 10.1056/NEJMc2307721 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37590457</ArticleId></ArticleIdList></Reference><Reference><Citation>Campello, E., Biolo, M. &amp; Simioni, P. More on Adenovirus-Associated Thrombocytopenia, Thrombosis, and VITT-like Antibodies. N. Engl. J. Med.389, 1729. 10.1056/NEJMc2310644 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37913522</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J. J. et al. Antibody fingerprints linking adenoviral anti-PF4 disorders. N. Engl. J. Med.390, 1827–1829. 10.1056/NEJMc2402592 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38749041</ArticleId></ArticleIdList></Reference><Reference><Citation>See, I. et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, december 2020 to august 2021. Ann. Intern. Med.175, 513–522. 10.7326/m21-4502 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8787833</ArticleId><ArticleId IdType="pubmed">35038274</ArticleId></ArticleIdList></Reference><Reference><Citation>Dautaj, A. et al. Hereditary thrombophilia. Acta Biomed.90, 44–46. 10.23750/abm.v90i10-S.8758 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233636</ArticleId><ArticleId IdType="pubmed">31577252</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorice, M. et al. Inhibition of protein S by autoantibodies in patients with acquired protein S deficiency. Thromb. Haemost.75, 555–559 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8743177</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson, H. M. et al. Activated protein C cofactor function of protein S: A critical role for Asp95 in the EGF1-like domain. Blood115, 4878–4885. 10.1182/blood-2009-11-256610 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884152</ArticleId><ArticleId IdType="pubmed">20308596</ArticleId></ArticleIdList></Reference><Reference><Citation>Regnault, V. et al. Anti-protein S antibodies following a varicella infection: Detection, characterization and influence on thrombin generation. J. Thromb. Haemost.3, 1243–1249. 10.1111/j.1538-7836.2005.01270.x (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15946215</ArticleId></ArticleIdList></Reference><Reference><Citation>Montserrat, B. et al. IgM anti-protein S antibodies as a risk factor for venous thrombosis. Haematologica93, 1115–1117. 10.3324/haematol.12575 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18508792</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin, M. et al. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J. Pediatr.127, 355–363. 10.1016/S0022-3476(95)70063-3 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7658262</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanne, T. M., Pedersen, A., Gisslén, M. &amp; Jern, C. Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19. Thromb. Res.204, 13–15. 10.1016/j.thromres.2021.05.016 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8163729</ArticleId><ArticleId IdType="pubmed">34102452</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarvand, P. &amp; Moser, K. A. Protein C deficiency. Arch. Pathol. Lab. Med.143, 1281–1285. 10.5858/arpa.2017-0403-RS (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30702334</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigada, M. et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost.18, 1738–1742. 10.1111/jth.14850 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906150</ArticleId><ArticleId IdType="pubmed">32302438</ArticleId></ArticleIdList></Reference><Reference><Citation>Tin, A. et al. Association between circulating protein C levels and incident dementia: The atherosclerosis risk in communities study. Neuroepidemiology55, 306–315. 10.1159/000516287 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8292178</ArticleId><ArticleId IdType="pubmed">34077937</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhanad, T. &amp; Lobelia, S. Antiphospholipid antibodies in COVID-19: A meta-analysis and systematic review. RMD Open7, e001580. 10.1136/rmdopen-2021-001580 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8103564</ArticleId><ArticleId IdType="pubmed">33958439</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineton de Chambrun, M. et al. High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: A link with hypercoagulability?. J. Intern. Med.289, 422–424. 10.1111/joim.13126 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307032</ArticleId><ArticleId IdType="pubmed">32529774</ArticleId></ArticleIdList></Reference><Reference><Citation>Siguret, V. et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?. Thromb. Res.195, 74–76. 10.1016/j.thromres.2020.07.016 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7342042</ArticleId><ArticleId IdType="pubmed">32663703</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles, L. et al. Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N. Engl. J. Med.383, 288–290. 10.1056/NEJMc2013656 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217555</ArticleId><ArticleId IdType="pubmed">32369280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca, D. L. M. et al. Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: A systems biology approach. npj Aging9, 21. 10.1038/s41514-023-00118-0 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10449916</ArticleId><ArticleId IdType="pubmed">37620330</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabit, J. Y., Valenzuela-Almada, M. O., Vallejo-Ramos, S. &amp; Duarte-García, A. Epidemiology of antiphospholipid syndrome in the general population. Curr. Rheumatol. Rep.23, 85. 10.1007/s11926-021-01038-2 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727975</ArticleId><ArticleId IdType="pubmed">34985614</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>